Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study

  • de Jong, M. A. [1], Wisaksana, R. [2], Meijerink, H. [3], Indrati, A. [4], van de Ven, A. J. [5], Alisjahbana, B. [6], van Crevel, R. [7],
  • Tropical Medicine & International Health : TM & IH
  • 17
  • Access here
  • Feb. 26, 2012
BIBLIOGRAPHY

de Jong, M. A., Wisaksana, R., Meijerink, H., Indrati, A., van de Ven, A. J., Alisjahbana, B., & van Crevel, R. (2012). Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study. Tropical Medicine & International Health : TM & IH, 17(5), 581–583. https://doi.org/10.1111/j.1365-3156.2012.02961.x
ABSTRAK

Many studies have evaluated the total lymphocyte count (TLC) as a cheap surrogate marker for CD4 cells in HIV-infected patients not receiving antiretroviral therapy (ART). We assessed whether TLC can replace CD4 cell counts in evaluating the immunological response to ART. In a cohort of patients in Indonesia TLC, if measured after at least 1-year ART, correctly identified patients with <200 CD4 cells, and reliably excluded immunological failure, obviating the need for CD4 cell measurement in 43% of patients.
ABSTRAK YANG BERHUBUNGAN